The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C
Hepatitis B Virus-Specific Antigens and AntibodiesUsed for Testing
Hepatitis B surface antigen (HBsAg): A protein on the surface of hepatitis B virus; it can be detected at high levels in serum during acute or chronic HBV infection. The presence of HBsAg indicates that a person is infected and infectious. The body normally produces antibodies to HBsAg as part of the normal immune response to infection. HBsAg is the antigen used to make hepatitis B vaccine.
Hepatitis B surface antibody (anti-HBs): The presence of anti-HBs is generally interpreted as indicating recovery and immunity from HBV infection. Anti-HBs also develops in a person who has been successfully vaccinated against hepatitis B.
Total hepatitis B core antibody (anti-HBc): This appears at the onset of symptoms in acute hepatitis B and generally persists for life. The presence of anti-HBc indicates previous or current infection with HBV in an undefined time frame.
IgM antibody to hepatitis B core antigen (IgM anti-HBc): Positivity indicates recent infection with HBV (less than 6 months). Its presence indicates acute infection.
SOURCE: CDC, 2009c.
United States could enhance HBV and HCV detection and help to close gaps in care, particularly in hard-to-reach populations.
Hepatitis B Virus Laboratory Testing Serologic markers can be used to identify the different phases of HBV infection (Box 5-6). The preferred laboratory test for detecting current HBV infection is for hepatitis B surface antigen (HBsAg), and the principal test for detecting recovery from HBV infection is for anti-HB surface antibody (anti-HBs). An alternative is to test initially for anti-HB core antibody (anti-HBc)—which is present during acute, chronic, and resolved HBV infection—and, if the result is positive, to conduct followup testing for HBsAg and anti-HBs. HBV markers can be misinterpreted by clinicians, and this can lead to clinical errors in patient evaluations, counseling, or treatment. For example, anti-HBc and anti-HBs can be misinterpreted as indicators of active infection (Weinbaum, 2008).